After signing up, you'll start to receive regular news updates from us.
Pluristem Receives $470,000 Grant from Israeli Government to Further Develop Stem Cell Product
Complete the form below to unlock access to ALL audio articles.
Pluristem Life Systems, Inc. has announced that its fully owned subsidiary Pluristem Ltd received a $470,000 grant from Israel's prestigious Chief Scientist Office (CSO).
The royalty-bearing grant is part of the Government's Ministry of Trade and Industry program that offers incentives to high-tech companies for capital investment, scientific research and development.
The monies were designated by the Chief Scientist Office to further develop first-time-recipient Pluristem's stem cell product PLX-I, a potential solution that could be used to replace the traditional bone marrow transplant search and match process.
Zami Aberman, CEO of Pluristem states, "We are excited that the CSO has recognized us as a leader in stem cell technology and proud they decided to support the development of PLX I."
"The grant will help us to complete additional animal studies and human clinical trials."
"PLX-I could then be offered to the medical community positioning Pluristem to capture a significant share of the $5 billion commercial bone marrow transplant market."
"It was always a privilege to be associated with such great technology and now to have the support of the government to bring it to market could add even more distinction to our advanced line of adult stem cell graft products."
